Elevated nuclear expression of the SMRT corepressor in breast cancer is associated with earlier tumor recurrence

[1]  Adrian V. Lee,et al.  Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer , 2010, Breast Cancer Research and Treatment.

[2]  Peter Regitnig,et al.  Genomic index of sensitivity to endocrine therapy for breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  S. Oesterreich,et al.  Cooperative activation of cyclin D1 and progesterone receptor gene expression by the SRC-3 coactivator and SMRT corepressor. , 2010, Molecular endocrinology.

[4]  W. V. van IJcken,et al.  CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer , 2009, British Journal of Cancer.

[5]  C. Dieli-Conwright,et al.  Oestradiol and SERM treatments influence oestrogen receptor coregulator gene expression in human skeletal muscle cells , 2009, Acta physiologica.

[6]  Xiwen Cheng,et al.  G Protein Pathway Suppressor 2 (GPS2) Is a Transcriptional Corepressor Important for Estrogen Receptor α-mediated Transcriptional Regulation* , 2009, The Journal of Biological Chemistry.

[7]  B. O’Malley,et al.  Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family , 2009, Nature Reviews Cancer.

[8]  John D. Minna,et al.  Molecular Profiling of Breast Cancer Cell Lines Defines Relevant Tumor Models and Provides a Resource for Cancer Gene Discovery , 2009, PloS one.

[9]  A. Sasse,et al.  Oral fluoropyrimidines versus 5-fluorouracil for colorectal cancer: Results of a systematic review and meta-analysis. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  S. Karmakar,et al.  Unique roles of p160 coactivators for regulation of breast cancer cell proliferation and estrogen receptor-alpha transcriptional activity. , 2009, Endocrinology.

[11]  Hung-Ying Kao,et al.  Cdk2 and Pin1 negatively regulate the transcriptional corepressor SMRT , 2008, The Journal of cell biology.

[12]  I. Ellis,et al.  The prognostic significance of steroid receptor co-regulators in breast cancer: co-repressor NCOR2/SMRT is an independent indicator of poor outcome , 2008, Breast Cancer Research and Treatment.

[13]  V. Speirs,et al.  Changes in expression of steroid receptors, their downstream target genes and their associated co-regulators during the sequential acquisition of tamoxifen resistance in vitro. , 2007, International journal of oncology.

[14]  E. Messing,et al.  Increased Expression of Corepressors in Aggressive Androgen-Independent Prostate Cancer Cells Results in Loss of 1α,25-Dihydroxyvitamin D3 Responsiveness , 2007, Molecular Cancer Research.

[15]  M. Goodson,et al.  Response of SMRT (silencing mediator of retinoic acid and thyroid hormone receptor) and N-CoR (nuclear receptor corepressor) corepressors to mitogen-activated protein kinase kinase kinase cascades is determined by alternative mRNA splicing. , 2007, Molecular endocrinology.

[16]  S. Karmakar,et al.  The Silencing Mediator of Retinoic Acid and Thyroid Hormone Receptor (SMRT) Corepressor Is Required for Full Estrogen Receptor α Transcriptional Activity , 2007, Molecular and Cellular Biology.

[17]  J. Selby,et al.  Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  S. Miettinen,et al.  Steroid hormone receptors and coregulators in endocrine‐resistant and estrogen‐independent breast cancer cells , 2006, International journal of cancer.

[19]  Myles Brown,et al.  Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-alpha and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT. , 2005, Molecular endocrinology.

[20]  M. Privalsky,et al.  SMRT and N-CoR Corepressors Are Regulated by Distinct Kinase Signaling Pathways* , 2004, Journal of Biological Chemistry.

[21]  M. Mayo,et al.  SMRT derepression by the IkappaB kinase alpha: a prerequisite to NF-kappaB transcription and survival. , 2004, Molecular cell.

[22]  M. Mayo,et al.  SMRT Derepression by the IκB Kinase α , 2004 .

[23]  F. Khanim,et al.  Altered SMRT levels disrupt vitamin D3 receptor signalling in prostate cancer cells , 2004, Oncogene.

[24]  R. Schiff,et al.  Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. , 2004, Journal of the National Cancer Institute.

[25]  S. Hilsenbeck,et al.  Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. , 2003, Journal of the National Cancer Institute.

[26]  E. Diamandis,et al.  Characterization of androgen receptor and nuclear receptor co‐regulator expression in human breast cancer cell lines exhibiting differential regulation of kallikreins 2 and 3 , 2002, International journal of cancer.

[27]  M. Dowsett,et al.  Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation , 2002, The Journal of Steroid Biochemistry and Molecular Biology.

[28]  E. Anderson.  Progesterone receptors – animal models and cell signaling in breast cancer: The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis , 2002, Breast Cancer Research.

[29]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[30]  Myles Brown,et al.  Molecular Determinants for the Tissue Specificity of SERMs , 2002, Science.

[31]  M. Pike,et al.  Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. , 2000, Journal of the National Cancer Institute.

[32]  J. Kurebayashi,et al.  Expression Levels of Estrogen Receptor-α, Estrogen Receptor-β, Coactivators, and Corepressors in Breast Cancer , 2000 .

[33]  M. Dowsett,et al.  Expression of nuclear receptor interacting proteins TIF-1, SUG-1, receptor interacting protein 140, and corepressor SMRT in tamoxifen-resistant breast cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  V. Cavaillès,et al.  Estrogen receptor cofactors expression in breast and endometrial human cancer cells , 1999, Molecular and Cellular Endocrinology.

[35]  C K Osborne,et al.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  D. Allred,et al.  Prognostic and predictive factors in breast cancer by immunohistochemical analysis. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[37]  B. O’Malley,et al.  Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. , 1997, Molecular endocrinology.

[38]  A. Harris,et al.  Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. , 1996, Cancer research.

[39]  B. Ljung,et al.  The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast. , 1992, Oncogene.

[40]  G. Hommel.  A stagewise rejective multiple test procedure based on a modified Bonferroni test , 1988 .

[41]  Neil J McKenna,et al.  GEMS (Gene Expression MetaSignatures), a Web resource for querying meta-analysis of expression microarray datasets: 17beta-estradiol in MCF-7 cells. , 2009, Cancer research.

[42]  D. Allred,et al.  Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study , 2005, Modern Pathology.

[43]  Arnold D K Hill,et al.  Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptor-estrogen response element by beta-estradiol and 4-hydroxytamoxifen in human breast cancer. , 2004, The Journal of clinical endocrinology and metabolism.